Two Toronto startups are developing psilocybin-based medications that could expand treatment options for those in need.

Psychedelic drugs had become more readily available to the public, and Witt—a contributor to publications including The New ...

More than 5 million Americans in treatment for depression could benefit from therapy with psilocybin -- the active ingredient ...

The U.S. Food and Drug Administration (FDA) has issued a complete response letter for MDMA-assisted psychotherapy (MDMA-AT) ...